



Impactful food solutions for our health and that of our planet.

KEEN Growth Capital's mission is to provide food and food as medicine solutions that provide measurable results, positive outcomes, and address food insecurity for the health and well-being of all.



CURRENT FUND III OPPORTUNITY


KEEN Growth Capital is raising a \$250 million Fund III to scale its Impact investment strategy—providing measurable societal outcomes in addition to above-market venture returns.

KEEN invests early stage, typically as the first professional capital in the venture which allows for tailoring both term sheet, ESG targets and overall governance. Focus is on businesses with strong IP and readiness to scale. Our experienced operational team accelerates speed to market and sustainable growth. This approach de-risks the portfolio and has historically provided above market venture returns.

FUND OVERVIEW

- \$250M**
Target Size
- 10-16 COMPANIES**
Portfolio Size
- \$3M - \$5M**
Investment Range
Seed & Series A with follow-ons to \$15M
- UNITED STATES**
Geography
- EARLY STAGE**
Company Size

LEADERSHIP



JONATHAN SMIGA

Managing Partner

- Leads Fund Management
- 30+ years of experience with world-class brands, consumer insights, private equity
- NYU Stern, MBA
- Cornell University, MMH



JERRY BELLO

Managing Partner

- Leads Portfolio Operations
- Serial entrepreneur & early investor whose leadership resulted in exits with 6-12x returns in Keen Fund I.
- Rutgers School of Pharmacy

INVESTMENT TARGETS



FUNCTIONAL FOODS

Foods & supplements that have a positive impact beyond basic nutrition.



FOOD AS MEDICINE

Evidence-based nutrition, with positive clinical outcomes that bridge the gap between food and pharma.



FOOD TECHNOLOGY

Emerging food technologies that are advancing food and health systems.

KEEN GROWTH CAPITAL FUND II

INVESTMENTS



PERFORMANCE

- AUM: Keen GP manages over \$100M in two parallel funds: KGC Fund II \$55.3M & KGC Co-Invest Fund II \$45M
- Returns: Combined - Net 38.6% IRR. Fund II - 15.2% IRR. Co-Invest Fund - 52.6% IRR.
- Exits: Keen is expecting a first exit by mid-year 2023 at a valuation that should return majority of all capital.
- GP Commitment: KEEN GPs have invested 12.3% of Fund II and anticipate a material contribution to Fund III.
- Fund III Institutional Sponsor: Keen's Fund II institutional sponsor has invested a total of \$65M between the 2 funds. They have expressed interest to lead Fund III proportional to complimentary fund raising.

GET IN TOUCH

Jonathan Smiga | Managing Partner | 949.500.5858 | jonathan@keengrowthcapital.com

This material is in connection with an unregistered security, which is suitable only for accredited investors. This security entails a high degree of risk, including loss of principal. Securities offered through Finalis Securities, LLC. Member FINRA and SIPC.